Hemab says HMB-001 was well tolerated in Phase 1 Glanzmann Thrombasthenia trial
HMB-001 is designed to bind and stabilise endogenous Factor VIIa using one antibody arm, while the second arm…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
12 Feb 24
HMB-001 is designed to bind and stabilise endogenous Factor VIIa using one antibody arm, while the second arm…
12 Feb 24
DISC-3405 is an investigational, anti-TMPRSS6 monoclonal antibody designed to increase hepcidin production and suppress serum iron
08 Feb 24
Under the terms of the deal, Jazz will secure all rights, patents, title, and interest in exchange for…
08 Feb 24
QSAM is focused on the development of therapeutic radiopharmaceuticals for primary and metastatic bone cancer and its initial…
07 Feb 24
The vaccine’s application is based on the positive findings from a Phase 3 immunogenicity trial that showed an…
07 Feb 24
Demonstrates new engineered functional hair follicles in humanized mice
06 Feb 24
Myalepta is indicated as a replacement therapy as an adjunct to diet to treat the complications of leptin…
06 Feb 24
The acquisition is expected to further expand and complement Novartis’ oncology pipeline while helping the firm to develop…
06 Feb 24
With this approval, IXCHIQ became the world’s first licensed chikungunya vaccine available to address this unmet medical need
05 Feb 24
The results from the Japanese trial were on par with the ATTRibute-CM trial in terms of survival rates,…